High-growth obesity Viking is actively pursuing oral and subcutaneous VK2735 for obesity with ongoing Phase 3 trials VANQUISH-1 and VANQUISH-2, signaling a clear commercial focus and potential near-term market entry opportunities for strategic partnerships, licensing, or co-promotion deals.

GLP-1/GIP platform VK2735's dual GLP-1 and GIP receptor agonist profile places Viking in a competitive space alongside established GLP-1 therapies, offering collaboration prospects with pharma companies seeking to broaden metabolic disease portfolios or to combine with complementary drugs.

Diversified pipeline Beyond VK2735, Viking is advancing VK2809 for lipid/metabolic disorders and VK3019 as a novel amylin/calcitonin receptor agonist, plus VK0214 for X-ALD, providing multiple entry points for regional partnerships, licensing deals, or milestone-driven collaborations across rare and prevalent indications.

Strong funding profile With substantial funding and a revenue run-rate in the tens of millions, Viking demonstrates financial viability for collaboration, joint ventures, or upfront licensing conversations, supported by a robust cash runway for late-stage development.

Strategic leadership changes Recent board expansion including new director appointments may indicate strategic pivots or enhanced governance to support larger partnerships, making timing favorable for outreach to engage in strategic advisory or co-development negotiations.